MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?

Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related deaths, posing a serious health risk. Despite new advances in immune checkpoint and targeted therapies in recent years, the prognosis for lung cancer patients, especially those in advanced stages, remains poor. MicroR...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules (Basel, Switzerland) Switzerland), 2023-05, Vol.13 (6), p.877
Main Authors: Yang, Han, Liu, Yufang, Chen, Longqing, Zhao, Juanjuan, Guo, Mengmeng, Zhao, Xu, Wen, Zhenke, He, Zhixu, Chen, Chao, Xu, Lin
Format: Article
Language:English
Subjects:
Cancer therapies
Care and treatment
Cell cycle
Cell growth
Chemoradiotherapy
Chemotherapy
Clinical trials
Combined Modality Therapy
Drug resistance
Genes
Genetic aspects
Health aspects
Humans
Immune checkpoint
Immunotherapy
Kinases
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Medical prognosis
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - therapeutic use
miRNA
MiRNA-based therapy
Proteins
Radiation therapy
Review
RNA, Small Interfering
siRNA
targeted therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related deaths, posing a serious health risk. Despite new advances in immune checkpoint and targeted therapies in recent years, the prognosis for lung cancer patients, especially those in advanced stages, remains poor. MicroRNAs (miRNAs) have been shown to modulate tumor development at multiple levels, and as such, miRNA mimics and molecules aimed at regulating miRNAs have shown promise in preclinical development. More importantly, miRNA-based therapies can also complement conventional chemoradiotherapy, immunotherapy, and targeted therapies to reverse drug resistance and increase the sensitivity of lung cancer cells. Furthermore, small interfering RNA (siRNA) and miRNA-based therapies have entered clinical trials and have shown favorable development prospects. Therefore, in this paper, we review recent advances in miRNA-based therapies in lung cancer treatment as well as adjuvant therapy and present the current state of clinical lung cancer treatment. We also discuss the challenges facing miRNA-based therapies in the clinical application of lung cancer treatment to provide new ideas for the development of novel lung cancer therapies.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom13060877